TY - JOUR
T1 - Pathology of mouse models of intestinal cancer
T2 - Consensus report and recommendations
AU - Boivin, Gregory P.
AU - Washington, Kay
AU - Yang, Kan
AU - Ward, Jerrold M.
AU - Pretlow, Theresa P.
AU - Russell, Robert
AU - Besselsen, David G.
AU - Godfrey, Virginia L.
AU - Doetschman, Thomas C
AU - Dove, William F.
AU - Pitot, Henry C.
AU - Halberg, Richard B.
AU - Itzkowltz, Steven H.
AU - Groden, Joanna
AU - Coffey, Robert J.
N1 - Funding Information:
Supported by the Mouse Models of Human Cancers Consortium sponsored by the National Cancer Institute.
PY - 2003/3/1
Y1 - 2003/3/1
N2 - The marked diversity in the phenotype of intestinal neoplasia in murine models offers opportunities to model many characteristics of human CRC, including tumor progression, metastasis, gross morphology, and histology. However, the lack of a consistent model of metastasis is of particular concern in developing mouse models of human CRC. AOM-treated mice consistently develop metastasis, but the absence of control by known genetic mutations under carcinogen treatment makes this model system less desirable. The Smad3-/-, PI(3)Kγ-/-,90 and Apc1638N/+ mutants are the only mouse models reported to develop colonic adenocarcinomas that metastasize to the lymph nodes and liver, which are common metastatic sites of human CRCs. However, there has been difficulty reproducing this observation in similar strains from different laboratories. Neoplastic lesions in mice with specific genetic alterations often do not parallel the phenotype of human cancer. Lastly, the role of intestinal pathogens and their contribution to the inflammatory response and tumor initiation is generally underappreciated. Despite these limitations, mouse models are invaluable in approximating the pathogenesis of human intestinal cancer and thus provide an in vivo platform for identifying therapeutic targets and developing new strategies for prevention and treatment.
AB - The marked diversity in the phenotype of intestinal neoplasia in murine models offers opportunities to model many characteristics of human CRC, including tumor progression, metastasis, gross morphology, and histology. However, the lack of a consistent model of metastasis is of particular concern in developing mouse models of human CRC. AOM-treated mice consistently develop metastasis, but the absence of control by known genetic mutations under carcinogen treatment makes this model system less desirable. The Smad3-/-, PI(3)Kγ-/-,90 and Apc1638N/+ mutants are the only mouse models reported to develop colonic adenocarcinomas that metastasize to the lymph nodes and liver, which are common metastatic sites of human CRCs. However, there has been difficulty reproducing this observation in similar strains from different laboratories. Neoplastic lesions in mice with specific genetic alterations often do not parallel the phenotype of human cancer. Lastly, the role of intestinal pathogens and their contribution to the inflammatory response and tumor initiation is generally underappreciated. Despite these limitations, mouse models are invaluable in approximating the pathogenesis of human intestinal cancer and thus provide an in vivo platform for identifying therapeutic targets and developing new strategies for prevention and treatment.
UR - http://www.scopus.com/inward/record.url?scp=0037370137&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037370137&partnerID=8YFLogxK
U2 - 10.1053/gast.2003.50094
DO - 10.1053/gast.2003.50094
M3 - Review article
C2 - 12612914
AN - SCOPUS:0037370137
SN - 0016-5085
VL - 124
SP - 762
EP - 777
JO - Gastroenterology
JF - Gastroenterology
IS - 3
ER -